Throughout the last three months, 8 analysts have evaluated Avidity Biosciences RNA, offering a diverse set of opinions from ...

Delpacibart zotadirsen is under clinical development by Avidity Biosciences and currently in Phase II for Duchenne Muscular Dystrophy.

Highlighted by Genentech's recent US regulatory submission for trastuzumab–DM1, antibody–drug conjugation technology could be heading for the mainstream in anticancer drug development.

Antibody–drug conjugates have emerged as a powerful tool to deliver highly targeted cancer therapies. Next-generation antibody-drug conjugate designs aim to push the envelope even further.

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design ...

CD Formulation’s dedication to precision and innovation extends to the development of Antibody Oligonucleotide Conjugates (AOCs), which harness antibodies for the selective delivery of therapeutic ...

with a Buy rating and $72 price target Three clinical programs establish Avidity’s Antibody Oligonucleotide Conjugate platform for future pipeline diversification, the analyst tells investors in ...

Avidity Biosciences, Inc. (NASDAQ:RNA) is rapidly growing into a potential leader in RNA-based genetic therapies, leveraging its Antibody Oligonucleotide Conjugates [AOCs] technology. Since my ...

The filing comes as the San Diego-based biotech is preparing to start a phase 3 clinical trials programme for its lead antibody oligonucleotide conjugate (AOC) – AOC 1001 for myotonic dystrophy ...

(Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on December 20 ...